16 drug varieties not included in the price linkage will be cleared by the hospital market

　　On April 28, the Guangxi Zhuang Autonomous Region Public Resources Trading Center issued a "Notice on the Suspension of the Qualification of Some Drug Online Trading", which does not include the price linkage of varieties, and will suspend the qualification of online trading from June, giving a clearance period of about one month
The notice shows that according to the work arrangement, for the 2015 Guangxi drug tender procurement shortlisted product catalog varieties of inter-provincial price linkage, has been divided into three batches to implement the linkage benchmark price, the 2019 inter-provincial price linkage has been implemented on April 27, 2020 In order to ensure the timely and effective linkage price, for varieties that are not included in the three instalments, online trading eligibility will be suspended from June 1, 2020 (clearing period: April 29, 2020 - May 31, 2020)
From the list of varieties suspended online trading qualification, a total of 16 varieties, 20 product rules, involving injection of lactose acid azithromycin, tempura injection, injection of cephalosporine sodium, etc., involving such as auxiliary medicine, Fu'an pharmaceutical industry Qing Yutang and other production enterprises
For varieties not included in the 2019 inter-provincial price linkage, the department will follow the deployment of the competent department of drug recruitment policy, make arrangements in the next round of centralized drug procurement, or carry out price correction according to the specific circumstances
According to the relevant regulations, public medical institutions at all levels are required to purchase drugs on the provincial drug collection platform, and are not allowed to purchase them online and through other channels This also means that the batch of drugs that guangxi suspended online trading qualification will not be available for procurement in the hospital market
On April 25, 2019, the Guangxi Zhuang Autonomous Region Medical Insurance Bureau and the Health and Health Commission jointly issued the Notice on Further Adjusting and Improving the Policy on the Central Procurement and Use of Medicines in Medical and Health Institutions, which made new provisions for controlling the unreasonable growth of drug prices and reducing the prices of inflated drugs It is clear that the price linkage adjustment is implemented once a year in principle After the price linkage of the shortlisted varieties is implemented, the relevant information is published on the drug procurement platform of the autonomous region, and the medical and health institutions are not allowed to negotiate the second time
In fact, in recent years, to be market-clearing varieties are not a minority, all over the relevant instructions For example, Hunan Province recently issued a notice, from May 1, Hunan drug collection system will be based on the antimicrobial drug winning results synchronously adjust the relevant catalog properties and price information The original has been hung up the net and does not in the anti-bacterial drugs winning the bid or linked to the network directory of drugs to stop hanging the net, the time will be notified
On April 17, Jiangsu Provincial Public Resources Trading Center issued a "Notice on the Public Notice on the Suspension of The Purchase of Drugs That Failed to Evaluate Drugs in Conformity with The Quality and Efficacy of Generic Drugs", suspending the procurement of 152 drugs, including amoxicillin capsules, omeprazole intestinal capsules, oxalic acid espresso tablets, etc
On the same day, the Shenzhen drug trading platform suspended the procurement of 8 drugs involving atoflavatin calcium tablets, fentanyl chlorpyrifos, amosilin capsules, acetaminophen tablets, mitanetablets, and pyridoxamine tablets
On April 13, the Beijing Pharmaceutical Collection Service Center issued "Notice on the suspension of the suspension of the national collection within the scope of partially failed to pass the consistent evaluation of product procurement function", more than 800 varieties were suspended procurement, involving Jiangsu Hengrui, Shi medicine Ouyi, Sichuan Kolun, Shijiazhuang four drugs, Lizhu Group, pharmaceutical and other well-known pharmaceutical companies
On the whole, the reasons for the suspension of the above-mentioned varieties from hanging the net mainly include failure to pass the consistency evaluation, not included in the price linkage and so on These market-cleared varieties will undoubtedly be affected in terms of market share.